Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KARS1 | Q15046 | 3/20 | 0.52 |
| ▸ | GPR55 | Q9Y2T6 | 5/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899168 | 0.92 | KARS1 (0.43) | KARS1NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL4900004 | 0.88 | KARS1 (0.43) | KARS1GPR55GRM5 | |
| SCHEMBL4905119 | 0.84 | CTSC (0.48) | KARS1CYP2A6CYP3A4 | |
| SCHEMBL4892104 | 0.83 | CYP2E1 (0.41) | KARS1CYP2A6NPC1TP53RAB9A | |
| SCHEMBL4902892 | 0.82 | KARS1 (0.40) | KARS1NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL4901584 | 0.81 | SLC2A1 (0.48) | KARS1NPC1RAB9ASMN1; SMN2GRM5 | |
| SCHEMBL4900205 | 0.81 | NPC1 (0.40) | KARS1NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL4901969 | 0.81 | KARS1 (0.40) | KARS1NPC1RAB9AGRM5ALDH1A1 | |
| SCHEMBL3142922 | 0.81 | CYP2A6 (0.51) | KARS1GPR55CYP2A6NPC1TP53 | |
| SCHEMBL4901420 | 0.80 | CYP2A6 (0.52) | KARS1GPR55CYP2A6NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | ICAGEN, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1737852-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100349-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | KCNJ2, KCNH2, KCNQ1 | KARS1 512/4885GPR55 1522/4885CYP2A6 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.